Table 1 Demographic and clinical characteristics
Overall (n = 493) | No endpoint (n = 470) | Endpoint (n = 23) | p-value | |
|---|---|---|---|---|
Age (years) | 46 (33–60) | 47 (33–59) | 37 (27–61) | 0.129 |
Male sex, n (%) | 285 (57.8%) | 274 (58.3%) | 11 (47.8%) | 0.321 |
Clinical history | ||||
Family history of SCD, n (%) | 62 (12.6%) | 59 (12.6%) | 3 (13.0%) | 0.945 |
Unexplained syncope, n (%) | 64 (13.0%) | 61 (13.0%) | 3 (13.0%) | 0.993 |
Known AF, n (%) | 84 (17.0%) | 75 (16.0%) | 9 (39.1%) | 0.004 |
Beta-blockers, n (%) | 364 (73.8%) | 346 (73.6%) | 18 (78.3%) | 0.621 |
Calcium channel blockers, n (%) | 52 (10.5%) | 49 (10.4%) | 3 (13.0%) | 0.690 |
ACEi/ARB, n (%) | 169 (34.3%) | 161 (34.3%) | 8 (34.8%) | 0.959 |
Holter monitoring data | ||||
NSVT, n (%) | 94 (19.1%) | 86 (18.3%) | 8 (34.8%) | 0.049 |
Echocardiography data | ||||
Left atrial size (mm) | 43 (38–47) | 42 (38–47) | 47 (40–52) | 0.025 |
MWT (mm) | 19 (16–23) | 19 (16–23) | 20 (17–26) | 0.213 |
MWT ≥ 30 mm, n (%) | 35 (7.1%) | 31 (6.6%) | 4 (17.4%) | 0.049 |
LVOTO (mm Hg) | 6 (3–50) | 6 (3–50) | 10 (3–48) | 0.472 |
LVOTO ≥ 30 mmHg, n (%) | 174 (35.3%) | 165 (35.1%) | 9 (39.1%) | 0.693 |
Exercise test dataa | ||||
Abnormal BP response, n (%) | 29 (10.2%) | 28 (10.3%) | 1 (9.1%) | 0.897 |
CMR data | ||||
LVEF (%) | 67 (61–70) | 67 (61–70) | 66 (55–70) | 0.259 |
LVEF 35–50%, n (%) | 16 (3.2%) | 13 (2.8%) | 3 (13.0%) | 0.007 |
Indexed EDV (mL/m2) | 73 (62–83) | 73 (62–83) | 76 (63–88) | 0.410 |
Maximum LV thickness (mm) | 21 (17–24) | 21 (17–24) | 23 (17–28) | 0.677 |
LV mass index (g/m2) | 92 (75–114) | 92 (75–114) | 90 (77–120) | 0.600 |
LGE present, n (%) | 391 (79.3%) | 368 (78.3%) | 23 (100%) | 0.012 |
LGE (g) | 5 (0.6–14.2) | 4.6 (0.6–13.8) | 26.3 (12.7–36.8) | < 0.001 |
LGE (%) | 2.9 (0.4–8.4) | 2.7 (0.3–7.7) | 12.0 (9.3–24.3) | < 0.001 |